Patients' willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection

Patient

Volumn 5, Issue 4, 2012, Pages 265-278

  Kauf, Teresa L ^a   Mohamed, Ateesha F ^b   Hauber, A Brett ^b   Fetzer, Derek ^c   Ahmad, Atiya ^c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Benefit risk assessment; Conjoint analysis; Hepatitis C; Patient preference; Peginterferon alfa; Ribavirin.

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; CLINICAL EFFECTIVENESS; FEMALE; FOLLOW UP; HEALTH SURVEY; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SELF REPORT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; ANTIVIRAL AGENTS; CHOICE BEHAVIOR; DECISION SUPPORT TECHNIQUES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERNET; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PREFERENCE; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84869169990     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.2165/11633580-000000000-00000     Document Type: Article

References (47)

1. Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003 Jul 9; 290 (2):228-37 (Pubitemid 37430062)
2. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 Apr; 39 (4):1147-71 (Pubitemid 38428955)
3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011 Aug; 55 (2):245-64
4. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007 Mar; 56 (3):385-9 (Pubitemid 46579770)
5. Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection: role of patient versus nonpatient factors. Hepatology 2007 Dec; 46 (6):1741-9
6. Markowitz JS, Gutterman EM, Hodes D, et al. Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C. J Viral Hepat 2005 Mar; 12 (2):176-85 (Pubitemid 40342176)
7. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C: patient, provider, and system factors. J Gen Intern Med 2005 Aug; 20 (8):754-8 (Pubitemid 41141009)
8. Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci 2007 May; 52 (5):1168-76 (Pubitemid 46626189)
9. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005 Apr 15; 40 Suppl. 5: S313-20
10. Nelson DR. Hepatitis C drug development at a crossroads. Hepatology 2009 Oct; 50 (4):997-9
11. Hauber AB, Mohamed AF, Beam C, et al. Patient preferences and assessment of likely adherence to hepatitis C virus treatment. J Viral Hepatitis 2011; 18 (9):619-27
12. Fraenkel L, Chodkowski D, Lim J, et al. Patients' preferences for treatment of hepatitis C. Med Decis Making 2010 Jan; 30 (1):45-57
13. Hensher DA, Rose JM, Greene WH. Applied choice analysis. Cambridge: Cambridge University Press, 2005
14. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000 Jun 3; 320 (7248):1530-3 (Pubitemid 30330316)
15. McFaddden D. Conditional logit analysis of qualitative choice behavior. In: Zarembka P, editor. Frontiers in econometrics. New York: Academic Press, 1974:105-42
16. Thurstone LL. A law of comparative judgment. Psychol Rev 1994; 101 (2):266-70
17. Ryan M, Scott DA, Reeves C, et al. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess 2001; 5 (5):1-186
18. Dey A. Orthogonal fractional factorial designs. New York: Halstead Press, 1985
19. Huber J, Zwerina K. The importance of utility balance in efficient choice designs. J Marketing Res 1996; 33:307-17
20. Kanninen B. Optimal design for multinomial choice experiments. J Marketing Res 2002; 39:214-27
21. Lipkus IM, Hollands JG. The visual communication of risk. J Natl Cancer Inst Monogr 1999; 25:149-63
22. Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007 Sep; 133 (3):769-79 (Pubitemid 47374126)
23. Train K.Discrete choice methods with simulation. Cambridge: Cambridge University Press, 2003
24. Train K, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Scarpa R, Alberini A, editors. Applications of simulation methods in environmental and resource economics. Dordrecht: Springer Publisher, 2005:117-34
25. Johnson FR, Hauber B, Ozdemir S, et al. Are gastro-enterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm 2010 Oct; 16 (8):616-28
26. Nahuelhual L, Loureiro ML, Loomis J. Using random parameters to account for heterogenous preferences in contingent valuation of public open spaces. J Agr Resource Econ 2004; 29 (3):537-52 (Pubitemid 40181140)
27. Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003 Apr; 9 (4):331-8 (Pubitemid 36443043)
28. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010 Feb; 138 (2):513-21
29. Davis GL, Roberts WL. The healthcare burden imposed by liver disease in aging baby boomers. Curr Gastroenterol Rep 2010 Feb; 12 (1):1-6
30. Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000 Oct; 90 (10):1562-9
31. Cotler SJ, Patil R, McNutt RA, et al. Patients' values for health states associated with hepatitis C and physicians' estimates of those values. Am J Gastroenterol 2001 Sep; 96 (9):2730-6
32. Schackman BR, Teixeira PA, Weitzman G, et al. Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? Med Decis Making 2008 Mar; 28 (2):233-42 (Pubitemid 351441944)
33. Bridges JF, Jones C. Patient-based health technology assessment: a vision of the future. Int J Technol Assess Health Care 2007; 23 (1):30-5 (Pubitemid 46648297)
34. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004 Apr; 40 (4):675-81 (Pubitemid 38367791)
35. Fredrickson BL, Kahneman D. Duration neglect in retrospective evaluations of affective episodes. J Pers Soc Psy-chol 1993; 65:44-55
36. Kahneman D, Fredrickson BL, Schreiber CA, et al. When more pain is preferred to less: adding a better end. Psychol Sci 1993; 4:401-5
37. Redelmeier DA, Kahneman D. Patients' memories of painful medical treatments: real-time and retrospective evaluations of two minimally invasive procedures. Pain 1996 Jul; 66 (1):3-8 (Pubitemid 26247018)
38. Varey C, Kahneman D. Experiences extended across time: Evaluation of moments and episodes. J Behav Decis Making 1992; 5:169-95
39. Schreiber CA, Kahneman D. Determinants of the remembered utility of aversive sounds. J Exp Psychol Gen 2000 Mar; 129 (1):27-42
40. Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health - a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011 Jun; 14 (4):403-13
41. Bridges JF, Kinter ET, Kidane L, et al. Things are looking up since we started listening to patients: trends in the application of conjoint analysis in health 1982-2007. Patient 2008; 1 (4):273-82
42. Mark TL, Swait J. Using stated preference and revealed preference modeling to evaluate prescribing decisions. Health Econ 2004 Jun; 13 (6):563-73 (Pubitemid 38787148)
43. Chang J, Kauf TL, Mahajan S, et al. Impact of disease severity and gastrointestinal side effects on the health state preferences of patients with osteoarthritis. Arthritis Rheum 2005 Aug; 52 (8):2366-75 (Pubitemid 41117421)
44. Hauber AB, Mohamed AF, Johnson FR, et al. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med 2009 Apr; 26 (4):416-24
45. Mohamed AF, Epstein JD, Li-McLeod JM. Patient and parent preferences for haemophilia A treatments. Haemophilia 2011 Mar; 17 (2):209-14
46. Buchanan T, Smith JL. Using the internet for psychological research: personality testing on the World Wide Web. Br J Psychol 1999 Feb; 90 (Pt 1):125-44
47. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey [online]. Available from URL: http://www.cdc.gov/nchs/ nhanes.htm [Accessed 2010 Dec 12]